EMCURE PHARMACEUTICALS
|
EMCURE PHARMACEUTICALS Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 48.76 | 35.96 | 27.50 | 29.42 | 36.62 |
| CEPS(Rs) | 71.54 | 57.61 | 46.37 | 45.45 | 52.39 |
| DPS(Rs) | 3.60 | 3.00 | 3.00 | 2.00 | 3.00 |
| Book NAV/Share(Rs) | 260.46 | 234.02 | 162.17 | 137.48 | 109.02 |
| Tax Rate(%) | 26.87 | 27.17 | 27.45 | 24.81 | 27.76 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 18.58 | 18.31 | 18.12 | 19.37 | 22.24 |
| EBIT Margin(%) | 15.23 | 14.30 | 14.21 | 15.76 | 19.21 |
| Pre Tax Margin(%) | 13.70 | 12.11 | 10.72 | 12.25 | 16.27 |
| PAT Margin (%) | 10.02 | 8.82 | 7.77 | 9.21 | 11.75 |
| Cash Profit Margin (%) | 14.44 | 13.61 | 12.38 | 13.48 | 15.84 |
| Performance Ratios | |||||
| ROA(%) | 10.70 | 8.94 | 7.39 | 8.97 | 11.15 |
| ROE(%) | 20.09 | 19.19 | 19.45 | 25.21 | 33.19 |
| ROCE(%) | 25.25 | 22.49 | 19.87 | 21.97 | 26.56 |
| Asset Turnover(x) | 1.07 | 1.01 | 0.95 | 0.97 | 0.95 |
| Sales/Fixed Asset(x) | 1.64 | 1.52 | 1.53 | 1.68 | 1.62 |
| Working Capital/Sales(x) | 5.53 | 4.25 | 6.50 | 7.47 | 13.02 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.61 | 0.66 | 0.66 | 0.60 | 0.62 |
| Receivable days | 88.68 | 87.83 | 94.32 | 88.49 | 84.97 |
| Inventory Days | 84.11 | 78.64 | 78.21 | 84.77 | 90.46 |
| Payable days | 176.65 | 174.97 | 193.72 | 194.85 | 188.82 |
| Valuation Parameters | |||||
| PER(x) | 32.73 | 29.84 | - | - | - |
| PCE(x) | 22.31 | 18.62 | - | - | - |
| Price/Book(x) | 6.13 | 4.58 | - | - | - |
| Yield(%) | 0.23 | 0.28 | - | - | - |
| EV/Net Sales(x) | 3.40 | 2.65 | 0.30 | 0.32 | 0.33 |
| EV/Core EBITDA(x) | 16.68 | 13.55 | 1.57 | 1.55 | 1.40 |
| EV/EBIT(x) | 21.89 | 18.21 | 2.10 | 1.98 | 1.69 |
| EV/CE(x) | 5.09 | 4.04 | 0.40 | 0.41 | 0.48 |
| M Cap / Sales | 3.29 | 2.57 | - | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | 16.56 | 18.59 | 11.23 | 2.23 | -3.32 |
| Core EBITDA Growth(%) | 21.77 | 19.81 | 4.86 | -11.93 | 9.94 |
| EBIT Growth(%) | 24.73 | 18.95 | 0.37 | -16.34 | 34.26 |
| PAT Growth(%) | 33.05 | 34.10 | -6.10 | -20.03 | 67.84 |
| EPS Growth(%) | 35.59 | 30.75 | -6.52 | -19.66 | 68.87 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.24 | 0.17 | 0.71 | 0.88 | 1.05 |
| Current Ratio(x) | 1.43 | 1.71 | 1.33 | 1.27 | 1.15 |
| Quick Ratio(x) | 0.82 | 0.98 | 0.85 | 0.81 | 0.67 |
| Interest Cover(x) | 9.96 | 6.53 | 4.07 | 4.50 | 6.53 |
| Total Debt/Mcap(x) | 0.04 | 0.04 | - | - | - |
Compare Financial Ratios of peers of EMCURE PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| EMCURE PHARMACEUTICALS | ₹36,584.6 Cr | 3.9% | -0.4% | 34.8% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹455,634.0 Cr | -2.9% | -2.3% | 21.8% | Stock Analytics | |
| DIVIS LABORATORIES | ₹241,576.0 Cr | -1.6% | 9.8% | 51.8% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹184,478.0 Cr | -2.6% | -2.3% | 37.5% | Stock Analytics | |
| CIPLA | ₹111,888.0 Cr | -2.2% | -6.1% | -12.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹96,322.1 Cr | -0.9% | -1.8% | -9.8% | Stock Analytics | |
EMCURE PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| EMCURE PHARMACEUTICALS | 3.9% |
-0.4% |
34.8% |
| SENSEX | -1% |
-2.6% |
-4.1% |
You may also like the below Video Courses
